Trial · NCT07893457
Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity
NCT07893457, Phase 4, Not yet recruiting, Mayo Clinic
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity. Trials, record NCT07893457. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07893457
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity
- NCT number
- NCT07893457
- Status
- Not yet recruiting
- Phases
- Phase 4
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Mayo Clinic
- Conditions
- Obese Adults
- Interventions
- Placebo, Tirzepatide
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Total Esophageal Acid Exposure Time During 96-Hour Wireless pH Monitoring | During the 96-hour wireless pH monitoring period, completed within 40 days after enrollment. | Percentage of total analyzable wireless pH recording time during which distal esophageal pH is less than 4. The value is calculated as the total duration with pH less than 4 divided by the total analyzable recording duration, multiplied by 100. One overall percentage is calculated for each participant across the monitoring period. Higher percentages indicate greater esophageal acid exposure. |
| Secondary | Number of Days With Abnormal Esophageal Acid Exposure During 96-Hour Wireless pH Monitoring | During the 96-hour wireless pH monitoring period, completed within 40 days after enrollment. | Number of interpretable 24-hour recording periods during which esophageal acid exposure time is greater than 6%. Acid exposure time is the percentage of analyzable recording time with distal esophageal pH less than 4. The outcome is a single count of abnormal recording days for each participant. |
| Secondary | Composite DeMeester Score During Wireless pH Monitoring | During the 96-hour wireless pH monitoring period, completed within 40 days after enrollment. | Composite DeMeester score calculated from the analyzable wireless esophageal pH recording. This outcome reports a single composite score for each participant. Higher scores indicate greater esophageal acid reflux burden. |
| Secondary | Esophagogastric Junction Distensibility Index Measured by Functional Lumen Imaging Probe | At the functional lumen imaging probe assessment, performed within 40 days after enrollment. | Esophagogastric junction distensibility index, expressed in square millimeters per millimeter of mercury (mm²/mmHg), measured using the functional lumen imaging probe at a balloon fill volume of 60 mL when intraballoon pressure is greater than 15 mmHg. Higher values indicate greater esophagogastric junction distensibility. |
| Secondary | Maximum Esophagogastric Junction Diameter Measured by Functional Lumen Imaging Probe | At the functional lumen imaging probe assessment, performed within 40 days after enrollment. | Maximum esophagogastric junction diameter, expressed in millimeters, measured using the functional lumen imaging probe. The reported value is the larger of the maximum diameters obtained at balloon fill volumes of 60 mL and 70 mL, yielding one maximum diameter for each participant. |
| Secondary | Resting Lower Esophageal Sphincter Pressure Measured by High-Resolution Manometry | At the high-resolution manometry assessment, performed within 40 days after enrollment. | Resting lower esophageal sphincter pressure, expressed in millimeters of mercury (mmHg), measured using high-resolution esophageal manometry. |
| Secondary | Integrated Relaxation Pressure Measured by High-Resolution Manometry | At the high-resolution manometry assessment, performed within 40 days after enrollment. | Integrated relaxation pressure, expressed in millimeters of mercury (mmHg), measured during standardized water swallows using high-resolution esophageal manometry. |
| Secondary | Mean Proximal Intragastric Pressure Before Seated Swallows | At the high-resolution manometry assessment, performed within 40 days after enrollment. | Mean proximal intragastric pressure during the preswallow interval of seated swallows, expressed in millimeters of mercury (mmHg). Pressure is measured using high-resolution manometry at a location 1 to 3 cm distal to the manometrically identified esophagogastric junction. |
| Secondary | Mean Proximal Intragastric Pressure During Swallow-Induced Esophagogastric Junction Opening | At the high-resolution manometry assessment, performed within 40 days after enrollment. | Mean proximal intragastric pressure during swallow-induced esophagogastric junction opening in the seated position, expressed in millimeters of mercury (mmHg). Pressure is measured using high-resolution manometry at a location 1 to 3 cm distal to the manometrically identified esophagogastric junction. |
| Secondary | Mean Proximal Intragastric Pressure Immediately After Swallow-Induced Esophagogastric Junction Closure | At the high-resolution manometry assessment, performed within 40 days after enrollment. | Mean proximal intragastric pressure immediately after esophagogastric junction closure following seated swallows, expressed in millimeters of mercury (mmHg). Pressure is measured using high-resolution manometry at a location 1 to 3 cm distal to the manometrically identified esophagogastric junction. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07893457
GET https://conductscience.org/api/trials/v1/NCT07893457/registered